RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma


OMX Stockholm

( %)

Hansa Biopharma in brief

We are leveraging our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.

From imlifidase, we have developed a first-in-class therapy to enable kidney transplantation in highly sensitized patients. The European Commission has conditionally authorized our first product for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

Our research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma is based in Lund, Sweden and with operations in other European countries and in the U.S.

Our Equity story

Learn more

Targeting rare diseases with a high unmet medical needs

Commercializing the first authorized product in first markets and indications

Evolving into a fully integrated biopharmaceutical company

Leveraging our proprietary antibody cleaving enzyme technology

green vials

Upcoming events


Annual Report 2022


Guggenheim Healthcare Talks Rare Disease Days


Redeye investor forum, Gothenburg

View all events
Latest Financial Results

Year-End Report January-December 2022

View all results

Press releases

Our latest press releases


Milestones and near-term news flow

  • GBS Phase 2 complete enrollment (H1 2023)
  • Anti-GBM Phase 3: First patient enrolled (H1 2023)
  • U.S. Kidney transplantation: Complete enrollment (H1 2023)
  • HNSA 5487 (Lead NiceR candidate) Initiate Phase 1 study (H1 2023)
  • Sarepta DMD pre-treatment: Commence Clinical study (2023)
  • Long-term follow-up study in kidney transplantation 5-year data readout (H2 2023)
  • AMR Phase 2: Full data readout (H2 2023)
  • GBS Phase 2: First data readout (H2 2023)
  • U.S. Kidney transplantation: Complete randomization (H2 2023)
  • U.S. Kidney transplantation BLA submission (2024)
Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.
Investor Relations

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709 298 269

Email: klaus.sindahl@hansabiopharma.com